Search for content, post, videos

Nordic Nanovector to explore strategic options

Nordic Nanovector
The Board has initiated this review aiming to optimize shareholder value following its recent decision to discontinue the PARADIGME study for Nordic Nanovector’s lead asset Betalutin and implement a restructuring of the company. The company's Board of Directors has appointed Carnegie Investment
Already a subscriber Login

You have read all your free articles, to continue reading subscribe to read the rest of this content.